A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis

Trial Profile

A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 23 Jun 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top